Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06717711 | Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers(RCT_LiESWT) | recruiting | Phase 3 | 158 | Regina Elena Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression(ASPENOVA) | recruiting | Phase 3 | 420 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
| 12 |
| Aug 12, 2026 |
| clinicaltrials |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | active not recruiting | Phase 3 | 129 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756008 | Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | not yet recruiting | Phase 2 / Phase 3 | 114 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT04269200 | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer(DUO-E) | active not recruiting | Phase 3 | 805 | AstraZenecaINDUSTRY | 22 | Aug 7, 2026 | clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy(GAIN-BCG) | recruiting | Phase 3 | 330 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03531099 | Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer(HIFUSA) | active not recruiting | Phase 3 | 108 | Hospices Civils de LyonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06476184 | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery(SALVOVAR) | recruiting | Phase 3 | 250 | ARCAGY/ GINECO GROUPOTHER | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 7 | Aug 4, 2026 | clinicaltrials |
| NCT06124976 | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 70 | Peter BlackOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse(PEACE 7) | recruiting | Phase 3 | 700 | UNICANCEROTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT01874353 | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | active not recruiting | Phase 3 | 327 | AstraZenecaINDUSTRY | 17 | Jul 29, 2026 | clinicaltrials |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma(STELLAR-304) | active not recruiting | Phase 3 | 317 | ExelixisINDUSTRY | 25 | Jul 29, 2026 | clinicaltrials |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)(ASCENT-GYN-01) | active not recruiting | Phase 3 | 640 | Gilead SciencesINDUSTRY | 19 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | active not recruiting | Phase 3 | 27 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | recruiting | Phase 3 | 710 | Daiichi SankyoINDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT05625360 | REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss | active not recruiting | Phase 3 | 160 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02303327 | Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | active not recruiting | Phase 3 | 307 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa(BiPASS) | recruiting | Phase 3 | 338 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | active not recruiting | Phase 3 | 412 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 24 | Jul 22, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT07207824 | DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC(HERO) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT07426055 | PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer(PRO-BOOST-LC) | recruiting | Phase 2 / Phase 3 | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07426094 | PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer(PRO-BOOST-N) | recruiting | Phase 2 / Phase 3 | 600 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC | recruiting | Phase 3 | 236 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03732677 | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC(NIAGARA) | active not recruiting | Phase 3 | 1,063 | AstraZenecaINDUSTRY | 22 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06746116 | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain(DUoENDE) | active not recruiting | Phase 3 | 45 | AstraZenecaINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
| NCT07286266 | A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) | recruiting | Phase 3 | 450 | GlaxoSmithKlineINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | active not recruiting | Phase 3 | 60 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT05804370 | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | recruiting | Phase 3 | 170 | NX Development CorpINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT07092566 | R.E.C.K vs Exparel in Robotic Nephrectomy | recruiting | Phase 3 | 170 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02319837 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 17 | Jul 9, 2026 | clinicaltrials |
| NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | Phase 3 | 400 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer(PAROLA) | recruiting | Phase 3 | 510 | Institut Claudius RegaudOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | recruiting | Phase 3 | 450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials